Publications

SpeeDx publications

Elisa Mokany, Simon Mark Bone, Paul Ean Young, Tram Bich Doan & Alison Velyian Todd. MNAzymes are a versatile new class of nucleic acid enzymes which can function as biosensors and molecular switches. J Am Chem Soc. 2010 January 27; 132(3): 1051-1059. Full text available here

MNAzymes featured in the literature

Genomeweb PCR Insider article: Nascent Australian firm SpeeDx seeks licensees, partners for 'MNAzyme' tech. April 01, 2010. View abstract here

Gerasimova et al. Nucleic acid detection using MNAzymes. Chem Biol. 2010 17(2): 104-106. View PubMed abstract here

Teller et al. Functional nucleic acid nanostructures and DNA machines. Curr opin Biotechnol. 2010 21: 1-16. View PubMed abstract here

Nauwelaers et al. Development of a real-time multiplex RSV detection assay for difficult respiratory samples, using ultrasone waves and MNAzyme technology. J Clin Virol. 2009 46(3): 238-43. View PubMed abstract here

Press Releases

19 September 2011

Universal Biosensors Advances Point-of-Care Molecular Diagnostic Opportunity

Universal Biosensors, Inc. (ASX: UBI) today announced that it has signed a non-exclusive licence
agreement with Australian company, SpeeDx Pty Ltd, for access to its proprietary MNAzyme technology.
The SpeeDx technology is a sensitive and highly selective method for detecting sequences of DNA or RNA. The agreement allows UBI to utilise SpeeDx’s proprietary technology in combination with UBI's proven diagnostic biosensor to access the rapidly growing molecular diagnostics market. UBI will seek to develop a molecular diagnostic platform that can deliver rapid, low cost results at the point-of-care.

Full text available here